SCHEDULE 13D

3540 Toringdon Way, Suite 200, #250, Charlotte, North Carolina 28277

The reporting person is the Executive Chairman and a director of Issuer.

No

No

Ontario, Canada

All of the shares of common stock to which this Schedule 13D relates were acquired by the Reporting Person in connection with the merger of Adaptin Acquisition Co. ("Acquisition Subsidiary"), a wholly-owned subsidiary of Adaptin Bio, Inc. (formerly known as Unite Acquisition 1 Corp., the "Issuer") with and into Adaptin Bio Operating Corporation (formerly known as Adaptin Bio, Inc., the "Company"), with the Company remaining and surviving as a wholly-owned subsidiary of the Issuer (the "Merger") pursuant to the Agreement and Plan of Merger and Reorganization, dated as of February 11, 2025 (the "Merger Agreement"), by and among the Issuer, Acquisition Subsidiary and the Company. Pursuant to the terms of the Merger Agreement, each issued and outstanding share of the Company's common stock was converted into and represented the right to receive such number of shares of Issuer common stock equal to the aggregate number of Company shares of common stock multiplied by the conversion ratio for that class or series, rounded up to the nearest whole share.

The Reporting Person acquired the common stock in connection with the Merger. The information contained in Item 3 of this Schedule 13D is incorporated herein by reference. The Reporting Person serves as the Executive Chairman and a director of the Issuer. Accordingly, the Reporting Person may have influence over the corporate activities of the Issuer, including activities that may relate to items described in clauses (a) through (j) of Item 4 of this Schedule 13D. Subject to the Lock-Up Agreement described in Item 6 of this Schedule 13D, the Reporting Person may, from time to time, purchase or sell securities of the Issuer as appropriate for his personal circumstances. Except as described in this Schedule 13D, the Reporting Person does not have any present plans or proposals that relate to or would result in any of the actions described in clauses (a) through (j) of Item 4 of this Schedule 13D. The Reporting Person reserves the right to formulate plans and/or proposals and to take such actions with respect to their investment in the Issuer, including any or all of the actions set forth in clauses (a) through (j) of Item 4 of this Schedule 13D.

928,571 - 11.5%

928,571

Except as otherwise described in this Schedule 13D, the Reporting Person has not effected any transaction related to the Issuer's common stock during the past 60 days.

Except as otherwise described in this Schedule 13D, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, securities covered by this Schedule 13D.

N/A

The information set forth in Item 3 is incorporated herein by reference. Lock-Up Agreements In connection with the execution of the Merger Agreement, all of the officers and directors of the Issuer following the Merger entered into lock-up agreements with the Issuer (the "Lock-Up Agreements") for a term ending two (2) years after the Issuer's common stock begins to trade on OTCQB or OTCQX market maintained by OTC Markets Group, the Nasdaq Stock Market, the New York Stock Exchange or the NYSE American, whereby they have agreed to certain restrictions on the sale or disposition (including pledge) of all of the Issuer's common stock held by (or convertible into or exercisable or exchangeable for shares of Issuer's common stock) the Reporting Person.

7.1 Agreement and Plan of Merger and Reorganization, among the Issuer, Acquisition Subsidiary and the Company, dated February 11, 2025 (incorporated by reference to Exhibit 2.1 to the Issuer's Current Report on Form 8-K as filed with the SEC on February 18, 2025). 7.2 Form of Lock-Up Agreement (incorporated by reference to Exhibit 10.5 to the Issuer's Current Report on Form 8-K as filed with the SEC on February 18, 2025).